PR
REGN icon

Payden & Rygel’s Regeneron Pharmaceuticals REGN Stock Holding History

Payden & Rygel’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,100
Closed -$10.2M – 132
2025
Q1 		$10.2M Buy
+16,100
New +$11.1M 0.88% 60

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Payden & Rygel's REGN Position: Q2 2025 in Review

Payden & Rygel sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 16,100 shares — an estimated $10.2M sold.

Payden & Rygel first reported a position in REGN in Q1 2025 and held it in 1 quarter. The position peaked at $10.2M in Q1 2025. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Payden & Rygel reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Payden & Rygel sold 16,100 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $10.2M.
  • Payden & Rygel first reported a position in Regeneron Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Payden & Rygel's Regeneron Pharmaceuticals position peaked at $10.2M in Q1 2025.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Payden & Rygel's 13F filing for Q2 2025, filed 7 Aug 2025.